HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop…
Castill Health Announces Plans for Philippines Digital Healthcare Launch, Supported by Craig Astill and Caason Group
PDF to PPT Converter From Presentations.AI Turns PDFs Into Editable PowerPoint Slide Decks With AI, Keeping Charts, Tables and Images Intact, as a Free-to-Try Gamma and Beautiful.ai Alternative
Hong Kong Autumn Electronics Fair and electronicAsia attract over 61,000 buyers for sourcing, business opportunities